Mohammad AskarPublic working copy · medical review pending

PPV and vitreoretinal surgery · 200

PPV: choose the retinal strategy and anticipate complications

Use the diagnosis, traction, lens status and actual anatomy to choose the operation and postoperative plan.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Maintain a safe view and controlled fluidics, release traction deliberately and distinguish urgent vascular/retinal disease from a fixed exam algorithm.

Terminology and draft status

Terminology review is not complete. No new WHO UMD entry verification is claimed; pending entries and limits are recorded in terminology.md.

01Surgical foundations: history and pressure balance

Pars plana vitrectomy (PPV) separates vitreous cutting/aspiration, illumination and infusion to address selected retinal problems. Endophthalmitis, diabetic tractional detachment, choroidal haemorrhage and panretinal photocoagulation (PRP) have different indications and safety priorities. 12

Historical teaching gives different dates: the shared lecture names Kasner 1961/Machemer 1970, while this own export uses 1974 for the three-port era or introduction. Priority and exact dates are unverified. Modern controlled infusion, illumination and cutting are the relevant functional principles, not a verified chronology or owner experience. 12 13

Separating infusion, illumination and working instruments allows controlled access and fluid management. Loss of infusion or excessive outflow can cause hypotony; neither the number of ports alone nor an unverified fixed pressure guarantees globe stability. 4

The original sequence runs from 17G to 23G, 25G and 27G. Gauge affects access, flow and instrument behaviour, but current model design, wound construction and the task matter more than an absolute “large for complex, small for simple” rule. 12 4

02Choose instruments and maintain a useful view

For firm diabetic membranes, consider instrument rigidity, available scissors and forceps, access and the intended dissection. A 27G instrument is not automatically inadequate, nor are all 23G or 25G instruments interchangeable. 4

The original viewing examples are wide-angle BIOM and Resight for peripheral work and contact lenses for macular detail. Choose a view that permits the required manoeuvre; lens magnification, stereopsis and illumination do not establish universal superiority or current product eligibility. 1 4

The original 20,000 cpm example has a device-specific counterpart: the 2022 EVA NEXUS submission describes TDC cutters driven at 10,000 cycles/min, cutting on both strokes. Effective cuts/min and mechanical cycles/min must not be treated as the same measurement. 4

Port geometry, duty cycle, aspiration, distance to the retina and tissue engagement all affect fluid movement and traction. The regulatory submission reports bench testing; it does not prove that high cut rate eliminates traction, creates uniformly laminar flow or prevents retinal tears. 4

The original brands Constellation/Unity, Stellaris Elite and EVA NEXUS are examples, not an independently verified precision ranking. BSS Plus contains bicarbonate, dextrose and oxidised glutathione after correct reconstitution; ordinary BSS and enriched formulations are not identical. Extra dextrose in every diabetic/phakic eye or compulsory epinephrine for every haemorrhage is not established. Use the actual compatible product/protocol and checked preparation rather than an unsourced additive recipe. 13 16

The original 20G-to-small-gauge history and a 60 Dcontact-lens example remain teaching context, not one compulsory lens or proof that no other viewing strategy permits PPV. Choose noncontact BIOM/Resight or contact magnification for the actual task and sufficient illumination, including selected chandelier illumination for bimanual work. 13

Irrigating solution is chosen to maintain suitable intraocular conditions, including corneal-endothelial and lens considerations during surgery. A compatible enriched formulation does not establish that adding glucose prevents every intraoperative lens opacity; preparation, concentration, exposure and the actual product instructions matter. 13 16

Choose instruments and maintain a useful view
GaugeApproximate incisionWound / instrument contextSelected uses and limits
23G0.6 mmOften rigid; inspect wound and suture if neededMay suit dense material/complex cases; not a compulsory dropped-lens gauge.
25G0.5 mmFlow, rigidity and seal depend on model/techniqueUseful in many routine ERM/RD procedures, not a guaranteed comfort/healing advantage.
27G0.4 mmFine access; flexibility and aspiration device-dependentNo universal maximum-comfort or dense-haemorrhage exclusion rule.

03Release traction and use dyes deliberately

Core vitrectomy creates working space; posterior vitreous detachment (PVD) induction aims to separate the posterior cortical vitreous. The optic-disc region is a familiar starting reference, but attachment and the safe plane vary; forceful induction can create retinal breaks. 1 2

Peripheral vitreous management and examination under scleral depression help identify residual traction or breaks. The vitreous base is firmly attached; aggressive attempts to remove every fibre can cause injury and are not a required manoeuvre for every macular hole. 1

The original sutureless example uses a 30–45° scleral tunnel. Wound architecture, gauge and actual leakage determine closure; “sutureless” is a design aim, not a reason to leave a leaking wound or to call every straight entry malpractice. 4

Triamcinolone can make residual vitreous visible, brilliant blue G preferentially stains ILM, and trypan blue is useful for epiretinal membrane staining. These agents have different targets and formulations; “safe for every membrane” is not an adequate product description. 1 5

Indocyanine green (ICG) improves contrast but concentration, exposure, illumination and subretinal contact influence toxicity. The original 30-second rule is not a universal validated safety boundary; use the specific intraocular product information and minimize unnecessary exposure. 1 5

Choose anaesthesia for duration, cooperation, comorbidity and surgical needs. Sub-Tenon access with blunt cannula after conjunctiva/Tenon opening, sometimes using Westcott scissors, is an option, not universally safest or risk-free. Upward eye position does not prove an effective block, and conjunctival ballooning alone does not prove wrong placement. Assess analgesia, akinesia and complications with the anaesthetic team. 13

The original phakic 4 mm and pseudophakic 3.0–3.5 mm limbal distances are adult teaching examples, not compulsory identical coordinates for every child, axial length or prior operation. Confirm pars-plana anatomy behind pars plicata, avoid lens/retinal injury, verify infusion position and inspect closure. The pars plana is a selected route, not an injury-proof “only safe zone”; bevelled access does not guarantee sealing or prevent all endophthalmitis. 13

Core vitreous contrast may appear silvery-white, but appearance alone does not identify every residual cortex. Triamcinolone/Kenalog can show vitreous and vitreoschisis; check formulation and indication rather than making it mandatory. A Weiss ring alone does not establish complete separation. Paediatric adhesion requires particular caution, not routine maximal aspiration over the disc; gas does not inevitably create tears whenever PVD induction is omitted. Peripheral shaving/depression is selected to see and relieve relevant traction, not guarantee removal of every fibre up to the ora. 13

Metamorphopsia can be more troublesome than a single acuity value in epiretinal membrane(ERM); assess both and the OCT. The original recurrence reduction from 10% to 2% after ILM peeling lacks a verified study population and follow-up here, and peeling has its own risks. Brilliant blue is not toxicity-free; ICG exposure must be minimised using the actual product. Selected macular holes need PPV/peeling/gas, but neither every large hole nor every ERM has the same technique or outcome. 13

For a large hole, the original>400 µm example prompts consideration of an inverted ILM flap, not a compulsory method for every eye. Small petechiae can occur during peeling but do not automatically prove harmlessness; inspect the plane, traction, illumination and any injury rather than dismissing all bleeding. Positioning benefits depend on the actual hole and procedure. 13

04Select a tamponade and monitor its consequences

Gas persistence depends on concentration, fill and the eye: this original gives SF6 about 2–3 weeks and C3F8 about 6–8 weeks, including a 14% C3F8 example. These are not personal clearance dates or proof that an “isoexpansile” mixture can never expand. Confirm the actual product and preparation; no flying, high altitude or nitrous oxide until all gas has gone and the team confirms safety. 3 13

Gas–fluid interfacial properties, contact and buoyancy contribute to tamponade; describing gases simply as having the highest surface tension is not a sufficient selection rule. Longer-acting tamponade for complex detachments or giant retinal tears is a separate decision from routine macular-hole repair. 1 3

The original comparison of 1000 cSt and 5000 cSt silicone oil concerns viscosity and handling. Higher viscosity may resist emulsification under some conditions, but both grades can emulsify; inflammation, impurities, time and ocular movement also matter. 6

In a randomised trial of 100 patients, both low- and high-viscosity oil groups developed emulsification and the difference was not statistically significant. That does not establish equivalence, validate every 1000/5000 cSt product comparison or mean that all proliferative vitreoretinopathy (PVR) requires one viscosity. 6

Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety. 3 12

Silicone oil is selected for some PVR/giant-tear or complex eyes; removal is planned individually and may be deferred or avoided in selected high-risk eyes, rather than compulsory for every patient. Posturing depends on pathology, technique and patient ability. Face-down 3–5 days is an original example, not mandatory for every macular hole; gas/air restrictions persist until actual complete clearance, regardless of the calendar. 3 13

Gas can support retinal apposition while laser adhesion develops in selected detachment repair. Nitrous oxide can enter an intraocular bubble rapidly and raise pressure enough to compromise central retinal arterial perfusion and cause irreversible visual loss; avoid it while any gas remains. This is a mechanism of risk, not a guarantee that every bubble or every pressure rise causes an arterial occlusion. 3 13

Select a tamponade and monitor its consequences
MediumApproximate persistenceClinical limits
AirAbout 1 week, variableNo flying/altitude/nitrous oxide while any bubble remains; not automatically safe after 1 week.
SF6 (20% example)About 2–3 weeks, variableConcentration/preparation affects expansion; calendar and 20% do not guarantee zero expansion.
C3F8 (14% example)About 6–8 weeks, variableLonger persistence; all gas restrictions until confirmed complete clearance.
Silicone oilPersists until removed; may be retained selectivelyRemoval/flight suitability individual; no universal compulsory removal, and exclude residual gas.

05Recognize other vitreoretinal emergencies and their evidence limits

Suspected postoperative endophthalmitis requires urgent sampling and antimicrobial treatment coordinated with vitreoretinal care. Do not delay treatment while applying an oversimplified visual-acuity rule. 7 8

EVS randomised 420 patients with endophthalmitis within 6 weeks of cataract surgery or secondary IOL implantation. Its immediate-PPV benefit concerned the light-perception-only subgroup; “≤ light perception” must not be generalized to no-light-perception eyes or every cause and modern setting. 7

The original intravitreal examples are vancomycin 1.0 mg/0.1 ml and ceftazidime 2.25 mg/0.1 ml. The historical ESCRS document lists ceftazidime 2 mg; these source-specific values are not a dilution recipe, and actual treatment requires a checked current local protocol and appropriate pharmacy preparation. 8

For diabetic tractional retinal detachment (TRD), segmentation and delamination release fibrovascular traction. The original optic-disc entry-plane example is a teaching approach, not proof that adhesions are always weakest or dissection safest there; choose the visible plane and avoid traction on adherent retina. 9

A sudden pressure change, loss of red reflex or suspected suprachoroidal bleeding during surgery requires immediate senior assessment and stabilization. The original “Portwine Blood” or “Hafenschlamm” description is not a diagnostic criterion or an instruction for routine high-pressure drainage. 10

Imaging, extent, apposition of detached choroidal elevations, pressure and retinal involvement guide whether and when drainage is considered. The evidence is dominated by heterogeneous observational reports; neither a single drainage technique nor one timing rule is established for every case. 10

Submacular haemorrhage in neovascular age-related macular degeneration (AMD) can prompt consideration of displacement, tPA and anti-VEGF treatment according to timing and anatomy. The original subretinal-tPA/air-or-gas example is one approach, not a universal treatment for blood beneath the macula. 11

STAR randomised 90 people to surgery or pneumatic displacement with tPA and anti-VEGF in both arms; 78 completed the 3-month endpoint. The adjusted visual-gain difference was 1.9 letters (95% CI −11.0–14.9; p=0.767): surgery was not superior, and equivalence was not established. 11

For rhegmatogenous detachment, compare buckling and PPV using break location, lens, PVD, traction, age and macular status. A young phakic eye without PVD may suit buckling because it avoids difficult induction and may preserve the lens, but the original<40 yearcutoff is not universal superiority proof and PPV does not cause inevitable cataract in every setting. Tobacco-dust pigment suggests a retinal break but does not replace careful examination. 13

When vitreous haemorrhage (VH) obscures the fundus, assess urgently and use B-scan to look for detachment or associated pathology. A negative scan cannot reliably exclude every small retinal tear: repeat assessment and retinal review may be necessary. A tear or detachment needs prompt specialist planning, while the urgency and choice of intervention depend on cause, macular threat and progression. Ghost cell glaucoma follows chronic vitreous haemorrhage: degenerated, rigid red cells block the trabecular meshwork. It is a reason to consider timely pars plana vitrectomy (PPV) in selected eyes with persistent haemorrhage, but it is not an automatic indication for surgery in every VH. 15

Fibrovascular membranes cause tractional retinal detachment (TRD). Macula-threatening or progressive detachment may require PPV with segmentation and delamination; stable extramacular traction is assessed individually. Gas or silicone oil tamponade depends on breaks, configuration and operative findings, and is not mandatory for every TRD. Preoperative anti-VEGF reduces vascularity but can make membranes contract abruptly — the “crunch” phenomenon — and worsen a TRD. The original instruction to operate “mandatorily within three to seven days” is a traditional precaution rather than a validated rule; the risk depends on how fibrotic the membranes are, and timing must be coordinated with the actual surgical list, sometimes earlier. 14

The original anti-VEGF 3–7 daypreoperative interval and>7–10 daycrunch warning are not validated universal safe/danger windows. Assess fibrosis and macular traction, coordinate a secure surgical plan before injection and arrange earlier review for worsening; do not inject without an operable plan simply to meet a memorised timetable. 13 14

For retained posterior lens material, assess pressure, inflammation, cornea, retinal detachment and infection. The original 7–14 day timing after IOP stabilisation is not a universal safe delay; uncontrolled pressure, infection or detachment can need earlier action. A fragmatome may be useful for selected dense material with appropriate vitreoretinal protection and equipment, not compulsory for every fragment. 13

Absent capsular support requires an individual secondary-IOL plan. The original “Acreos” model spelling/identity and 6-0 Prolene or Gore-Tex examples remain product/source questions, not one universal standard or verified material-inflammation ranking against Vicryl. Confirm the actual IOL, fixation, suture eligibility and long-term risks rather than inferring approval from a teaching name. 13

Suspected intraocular foreign body(IOFB/IOFK) needs urgent globe/retinal and infection assessment, protective handling and appropriate imaging; avoid MRI when metal is possible. Stabilise and repair the globe as indicated and plan safe vitreous release and controlled extraction. A blanket “infusion OFF until forceps grasp” can cause dangerous hypotony and is not a universal rule; inflow, object position and secure visualisation must be controlled together. 13

06Review the indication, manoeuvre and limitation together

Recall 1: A gas-filled eye needs emergency general anaesthesia. Tell the anaesthetist the gas identity/status and avoid nitrous oxide; it can rapidly enlarge the bubble and cause a sight-threatening pressure rise. Coordinate essential emergency care, and keep the restriction until the bubble is completely gone. 3 13

Recall 2: A metallic IOFB needs removal. Assess open-globe repair, infection and the object’s position; protect the retina and release adherent vitreous before controlled extraction. Do not apply a universal infusion-off command: balance secure object control against hypotony and pressure fluctuations, with direct visualisation and specialist equipment. 13

Recall 3: When might buckling suit detachment better than PPV? Consider a young phakic eye without PVD and a suitable break pattern, including the original<40 year teaching example. Lens preservation and avoiding difficult induction are potential advantages, not an age-only rule or proof that all PPV causes inevitable cataract. 13

Review the indication, manoeuvre and limitation together
PathologySelected strategyTamponade contextSafety / limits
RD(young/phakic)Consider buckle if break/PVD findings suitOften no internal tamponade for buckle aloneAge alone does not choose surgery; assess actual PVD/lens/breaks.
Diabetic TRDSegmentation/delaminationGas/oil only when findings requirePlan anti-VEGF/surgery together; no fixed crunch-safe interval.
Macular holeSelected ILM peel or inverted flapSelected SF6/C3F8/other planFace-down not compulsory for every hole; individual ability and evidence matter.
Dropped lensSelected fragmatome/retinal protectionBSS/air or other support by findingsControl pressure/inflammation;7–14 days not universal safe delay.
EndophthalmitisUrgent sampling/intravitreal treatment and selected PPVNot a mechanical tamponade substituteTap-and-inject is not one regimen for every case; postinjection infection needs urgent care.
What are the main learning points?

Maintain a safe view and controlled fluidics, release traction deliberately and distinguish urgent vascular/retinal disease from a fixed exam algorithm.

When is assessment urgent?

Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety.

References and access status

  1. 1
    AAO — Idiopathic Macular Hole PPP,2025

    Historical Review 015 recorded access reused without a fresh full-source claim: Actual official PDF; selected clinical recommendations/text and extracted tables printed P 243–P 255 read. Not full methodology, figures or every cited paper. Prose/table pneumatic-vitreolysis tension remains in the evidence record.

  2. 2
    Duker et al. — IVTS classification,2013; PMID 24053995

    Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract and selected original classification text read; original table 1 printed 2612 rendered and visually checked for units/inequalities. Not complete paper or all figures; table/body boundary wording differs.

  3. 3
    RCOphth — intraocular gas/nitrous-oxide safety alert,2018

    Historical Review 015 recorded access reused without a fresh full-source claim: Actual official page, gas table and recommendations read; cited case reports not fully read. No fixed individual clearance date inferred.

  4. 4
    FDA — EVA NEXUS K213467,14 June 2022

    Historical Review 015 recorded access reused without a fresh full-source claim: Selected actual regulator letter, device/cutter characteristics and bench-testing passages read. Historical configuration, not current full IFU, clinical superiority or EU authorization; original historical/gauge claims remain unresolved.

  5. 5
    DailyMed — TissueBlue current hosted label,version 8/effective 20260417

    Historical Review 015 recorded access reused without a fresh full-source claim: Main indication, administration, warning, adverse-effect, description and mechanism text read. US label, not German information. Structured quantity/date anomalies stay documented; no silent formulation inference.

  6. 6
    Ratanapakorn et al. — oil-viscosity randomized trial,2020; PMID 32103882

    Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read. Exact oil viscosities, outcome denominators and full methods need further access; do not relabel it as every original product comparison.

  7. 7
    Endophthalmitis Vitrectomy Study,1995; PMID 7487614

    Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read; full paper/protocol unread. Historical postoperative-cataract population; not a current universal emergency or dosing algorithm.

  8. 8
    ESCRS — endophthalmitis guideline,2013/current linked 2018 file

    Historical Review 015 recorded access reused without a fresh full-source claim: Actual official cover/contents and selected acute-treatment/preparation discussion/table 20 printed 22–23 read as text. Not full guideline or preparation appendix; original ceftazidime 2.25 mg differs from this historical 2 mg source.

  9. 9
    Retained original PPV/TRD/PRP teaching lecture

    Historical Review 015 recorded access reused without a fresh full-source claim: Original linked lecture identity retained; video, slides and exact transcript not inspected. Unresolved procedural/anatomical claims are teaching material, not verified recommendations; dedicated cross-page review pending.

  10. 10
    Ribeiro et al. — perioperative SCH systematic review,2024; PMID 39169423

    Historical Review 015 recorded access reused without a fresh full-source claim: Complete indexed abstract and selected primary introduction/methods read; full tables/reports unread. Mostly case reports/series; no standardized drainage approach.

  11. 11
    Gabrielle et al. — STAR randomized trial,2023; PMID 37088447

    Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read through NCBI E-utilities; full paper, protocol and supplements unread. Superiority not shown is not equivalence.

  12. 12
    Own immutable original export: review 192

    Own full clinical export read 17 November 2026; recording and attribution unverified.

  13. 13
    Own immutable original export: review 200

    Own full clinical export and wrapper inventories read 17 November 2026; recording, speaker and blanket guideline claims unchecked.

  14. 14
    German S3 guideline on retinal complications of diabetes 2025 (AWMF 045-024)

    Historical Review 123 access retained without new complete retrieval: Historical selected access reused from earlier review ledgers and editorially compared; no fresh complete retrieval or full-source appraisal claimed. Exact prior scope is recorded in evidence.md.

  15. 15
    Shaikh N, Srishti R, Khanum A, et al. Vitreous hemorrhage — causes, diagnosis, and management. Indian J Ophthalmol 2023;71:28-38. PMID 36588205

    Historical Review 123 access retained without new complete retrieval: Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, tables and supplements not appraised.

  16. 16
    BSS PLUS official hosted US label: composition

    Indexed official composition passage inspected 17 November 2026: bicarbonate, dextrose and oxidised glutathione are already present in reconstituted product. Not complete current label, preparation protocol, German eligibility or additive-safety appraisal.

Original lecture link